Coronary Artery Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Studies have provided controversial results regarding whether variations in the proprotein convertase subtilisin/kexin type 9 gene ( PCSK9) are risk factors for CAD.
|
30947598 |
2020 |
Coronary Artery Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Few studies have investigated the relationship between PCSK9 levels and the severity of coronary artery disease in patients with acute coronary syndrome; thus, we herein aimed to investigate this relationship in patients with non-ST-elevation myocardial infarction (NSTEMI) who underwent coronary angiography.
|
31206403 |
2020 |
Coronary Artery Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
A significant increase in plasma PCSK9 concentrations was observed with greater CAD severity (p = .042).
|
31493378 |
2019 |
Coronary Artery Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Although lipid-lowering drugs, especially statins, and recently also PCSK9 inhibitors can reduce LDL cholesterol (LDL-C) and decrease the risk for cardiovascular disease (CVD) including coronary artery disease (CAD) events most efficiently, only 5-10% of high-risk cardiovascular patients reach the target values recommended by international guidelines.
|
31818446 |
2019 |
Coronary Artery Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort.
|
31207358 |
2019 |
Coronary Artery Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
The addition of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, evolocumab, to statin therapy produced incremental regression of atherosclerotic plaques and a collaborative prevention of cardiovascular events in patients with coronary artery disease.
|
31495548 |
2019 |
Coronary Artery Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peptide inhibitors designed to block PCSK9-LDLR interactions could reduce the risk of CAD.
|
31452340 |
2019 |
Coronary Artery Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Correction to: Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese.
|
30076455 |
2019 |
Coronary Artery Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We measured PCSK9 and Lp(a) levels in plasma samples from Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events trial patients with coronary heart disease and/or type II diabetes (T2D) mellitus.
|
29103916 |
2019 |
Coronary Artery Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
We conducted a comprehensive search of electronic databases, up to December 1, 2018, for all RCTs comparing PCSK9 inhibition to placebo or ezetimibe in patients with hypercholesterolemia or coronary artery disease receiving maximally tolerated statin for primary or secondary prevention of mortality and cardiovascular outcomes.
|
31679643 |
2019 |
Coronary Artery Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Loss-of-function mutations in PCSK-9 gene invariably translates into lower levels of LDL, and decreased risk of developing coronary artery disease.
|
30953636 |
2019 |
Coronary Artery Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Soon after, studies uncovered the role of PCSK9 in the regulation of LDL-receptor recycling and identified loss-of-function variants of PCSK9 that were associated with low circulating levels of LDL cholesterol (LDL-C) and a reduced risk of coronary artery disease.
|
30420622 |
2019 |
Coronary Artery Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
However, in the non-statin group, PCSK9 levels in patients with CAD were significantly higher than those in patients without CAD.
|
29974199 |
2019 |
Coronary Artery Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Elevated levels of PCSK9 were positively associated with the development of CAD and future cardiovascular events, suggesting that measurement of PCSK9 concentration might be useful for cardiovascular risk stratification.
|
31711505 |
2019 |
Coronary Artery Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Aim was to estimate the genotypic distribution and risk allele frequencies of 13 Coronary Artery Disease (CAD) risk Single Nucleotide Polymorphisms in loci identified by the CARDIoGRAMplusC4D consortium namely MIA3 rs17465637; 9p21 rs10757274; CXCL12 rs1746048; APOA5 rs662799; APOB rs1042031; LPA rs3798220; LPA 10455872; MRAS rs9818870; LPL rs328; SORT1 rs646776; PCSK9 rs11591147; APOE rs429358; APOE rs7412 in Pakistani PCAD patients and controls.
|
28705542 |
2019 |
Coronary Artery Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
PCSK9 inhibitor prescribing increased over time for patients with coronary artery disease or coronary heart disease but not for those with dyslipidemia.
|
31020929 |
2019 |
Coronary Artery Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Background Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) has been reported to be related to several risk factors and diseases such as inflammatory markers and coronary artery disease.
|
28166668 |
2018 |
Coronary Artery Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mean PCSK9 was similar in patients with and without obstructive CAD at both CCTA and ICA.
|
30137516 |
2018 |
Coronary Artery Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Finally, the correlation of PCSK9 and Lp(a) with the presence and severity of CAD and peripheral artery disease (PAD) was assessed.
|
30170223 |
2018 |
Coronary Artery Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to characterize the alterations in the lipidome of plasma and lipoprotein particles after administration of PCSK9 inhibiting antibody to patients with established coronary heart disease.
|
29366988 |
2018 |
Coronary Artery Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Triglyceride-lowering alleles in LPL were associated with protection from coronary disease (approximately 40% lower odds per SD of genetically lower triglycerides) and type 2 diabetes (approximately 30% lower odds) in people above or below the median of the population distribution of LDL-C-lowering alleles at 58 independent genomic regions, HMGCR, NPC1L1, or PCSK9.
|
30326043 |
2018 |
Coronary Artery Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
A state transition Markov model was developed to model the cost-effectiveness of PCSK9 inhibitors for prevention of coronary heart disease, ischaemic strokes, and death among high-risk patient subpopulations in Norway, in both primary and secondary settings.
|
28444187 |
2018 |
Coronary Artery Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The frequencies of the AA, AG and GG genotypes of PCSK9 E670G polymorphism were 90.58, 9.27, and 0.16% in the CAD patients, compared with 88.72, 10.85 and 0.43% in the controls, respectively.
|
30205809 |
2018 |
Coronary Artery Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mature PCSK9 associated with atheroma volume and impaired vessel remodeling in HeFH patients with coronary artery disease.
|
28502498 |
2018 |
Coronary Artery Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
PCSK9 has emerged as a target for lipid-lowering therapy, but the predictive value of the serum level of PCSK9 for the severity of coronary disease is largely unknown.
|
29885102 |
2018 |